Advanced Basal Cell Carcinoma (BCC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The most frequent type of skin cancer is basal cell carcinoma (BCC), and advanced basal cell carcinoma is a more complicated variation of BCC. The majority of non-melanoma skin cancers (NMSCs) are BCCs, which are also more prevalent than all other types of cancer in humans. In the white population, the estimated lifetime risks for BCC are 23-28% for women and 33-39% for men. Every 25 years, the incidence of BCC doubles. Basal cell carcinoma (BCC) treatment aims to remove the tumor while maximizing function and appearance, according to the National Comprehensive Cancer Network (NCCN). The National Comprehensive Cancer Network (NCCN) states that the aim of treatment for basal cell carcinoma (BCC) is to remove the tumor while maximizing function and appearance.

Description

Advanced basal cell carcinoma is a nonmelanocytic skin cancer, which is the most typical type of skin cancer. Basal cells, or small, rounded cells found in the lower layer of the epidermis, are the source of BCC. Patients with BCC have an excellent prognosis, but the disease can have serious morbidity if it is allowed to advance. The majority of non-melanoma skin cancers (NMSCs) are BCCs, which are also more prevalent than all other types of cancer in humans taken together. The incidence of BCC is thought to be rising globally, and one variety of BCC that has penetrated deeper into the tissues is advanced basal cell carcinoma. It can appear differently depending on how its being looked at, but it typically consists of a single shiny lump with large blood vessels. It usually grows slowly, but it needs to be treated quickly. BCCs typically develop on the face, head (including the scalp), and neck, but they can also show up on the trunk, the extremities, or, less frequently, the hands. Given that BCC rarely metastasizes, laboratory and imaging tests are not typically clinically indicated in patients who present with localized lesions. When clinical suspicion exists that deeper structures, such as the bone, may be involved, imaging studies may be required. Ct scans or radiography may be used in these circumstances.

Advanced Basal Cell Carcinoma (BCC) (Epidemiology)

The estimated lifetime risk of BCC in the white population is 33-39% for men and 23-28% for women. BCC doubles in incidence every 25 years. Additionally, BCC incidence varies across the globe. South Africa and Australia, which receive a lot of UV radiation, have the highest incidence of skin cancer. Australia tends to have an increased incidence of BCC, while Finland has reported a lower incidence, approximately a quarter of the Minnesota incidence; however, the incidence of BCC also seems to be increasing in Finland, especially among younger women. BCC is the least likely cancer to metastasize. In contrast to squamous cell carcinoma, which makes up 16%of skin cancers and is more dangerous to life, BCC is less deadly. Despite the fact that BCC is seen in people of all races and skin tones, those with dark skin rarely experience it, and those with light skin (type 1 or type 2) experience it most frequently. BCC is most common among white people of Celtic ancestry. Men are impacted twice as frequently as women historically. Currently, the male to female ratio is about 2.1:1. Although the incidence of these skin cancers has been rising for some time, deaths from them are still relatively rare.

Advanced Basal Cell Carcinoma (BCC) -Current Market Size & Forecast Trends

The global market for advanced BCC therapies was valued at $5.34 billion in 2023. Growth is driven by the adoption of Hedgehog pathway inhibitors like Vismodegib and Sonidegib. The market is projected to grow at a CAGR of ~8% by 2035, as awareness and access to these therapies increase.

For nearly all cases of renal cell carcinoma, surgery is the suggested course of action. Depending on the tumor's size, depth, and location, a surgical strategy is chosen. Almost all treatments can be administered by a dermatologist in an outpatient setting. The majority of treatments are well-organized and widely accessible, but there are also additional choices (such as photodynamic therapy using photosensitizers). In some cases of renal cell carcinoma, local chemotherapy and immunomodulatory therapy are beneficial. These substances may have an effect on BCCs, particularly those that are small and superficial. For the treatment of superficial, non-serious melanomas with a diameter under 2 cm, topical imiquimod 5% is used which has been approved by the FDA. Typically, lesions are treated once daily, five days a week, for six to twelve weeks. Also, topical fluorouracil is applied twice daily for 3-6 weeks which is FDA-approved for the treatment of superficial melanoma. Although there are no definite formal limitations on fluorouracil use based on lesion size or location, it is typically reserved for smaller, superficial BCCs on the body and extremities. When treating potentially subclinical tumors, both imiquimod and fluorouracil can be applied topically to keep patients at risk for multiple BCCs healthy. Invasive BCC, morphogenic [sclerotic] BCC, small-volume BCC, and recurrent BCC are examples of tumors that are more difficult to treat and require mohs surgery, as do tumors where it is crucial to preserve healthy (non-cancerous) tissue. For patients who are not scheduled for surgery, radiation therapy is the main treatment choice. When surgical margins are positive, it can also be applied as adjuvant therapy. Radiation therapy, however, should not be used on patients who have skin cancer-predisposing genetic disorders. Inhibitors of the hedgehog pathway (HHI) are recommended for the treatment of patients with locally advanced metastatic BCC who are ineligible for surgery or radiation therapy or whose disease has returned after receiving either of these treatments. Both Sonidegib (Odomzo) and Vismodegib (Erivedge), the first and second HHI pathway inhibitors, received FDA approval in 2012. Arsenic trioxide and itraconazole therapy may ne used for patients with metastatic BCC that are HHI-resistant. The first immunotherapy, cemiplimab (Libtayo), was approved in February 2021 for treating locally advanced BCC patients who were also ineligible for HHI.

Report Highlights

Advanced Basal Cell Carcinoma (BCC) - Current Market Trends

Advanced Basal Cell Carcinoma (BCC) - Current & Forecasted Cases across the G8 Countries

Advanced Basal Cell Carcinoma (BCC) - Market Opportunities and Sales Potential for Agents

Advanced Basal Cell Carcinoma (BCC) - Patient-based Market Forecast to 2035

Advanced Basal Cell Carcinoma (BCC) - Untapped Business Opportunities

Advanced Basal Cell Carcinoma (BCC) - Product Positioning Vis-a-vis Competitors' Products

Advanced Basal Cell Carcinoma (BCC) - KOLs Insight